Lorell Discenza

Discovery of Dapagliflozin: A Potent, Selective Renal Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes

Wei Meng, Bruce A. Ellsworth, Alexandra A. Nirschl et al. · Journal of Medicinal Chemistry · 2008 · 612 citations · Full text

Metabolic Syndrome, Diabetes Management, Biochemistry +10

BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR

Joan M. Carboni, Mark D. Wittman, Zheng Yang et al. · Molecular Cancer Therapeutics · 2009 · 278 citations · Full text

Small Molecule Inhibitor, Cancer Biology, Insulin Signaling +16

In Vitro Characterization and Pharmacokinetics of Dapagliflozin (BMS-512148), a Potent Sodium-Glucose Cotransporter Type II Inhibitor, in Animals and Humans

Mary T. Obermeier, Ming Yao, Ashish Khanna et al. · Drug Metabolism and Disposition · 2009 · 176 citations

Discovery of 6-Fluoro-5-(<i>R</i>)-(3-(<i>S</i>)-(8-fluoro-1-methyl-2,4-dioxo-1,2-dihydroquinazolin-3(4<i>H</i>)-yl)-2-methylphenyl)-2-(<i>S</i>)-(2-hydroxypropan-2-yl)-2,3,4,9-tetrahydro-1<i>H</i>-carbazole-8-carboxamide (BMS-986142): A Reversible Inhibitor of Bruton’s Tyrosine Kinase (BTK) Conformationally Constrained by Two Locked Atropisomers

Scott H. Watterson, George V. De Lucca, Qing Shi et al. · Journal of Medicinal Chemistry · 2016 · 142 citations · Full text

Discovery of Branebrutinib (BMS-986195): A Strategy for Identifying a Highly Potent and Selective Covalent Inhibitor Providing Rapid in Vivo Inactivation of Bruton’s Tyrosine Kinase (BTK)

Scott H. Watterson, Qingjie Liu, Myra Beaudoin Bertrand et al. · Journal of Medicinal Chemistry · 2019 · 104 citations · Full text

Tyrosine Kinase, Immunology, Quantitative Pharmacology +20